In this article
Gliomas Introduction
Brain gliomas, especially aggressive types such as glioblastoma multiforme (GBM), have long been extremely challenging to treat because of their insensitivity to traditional therapies. But this breakthrough has come with the availability of ONC201 capsules in China, which presents new hope for patients fighting this crippling disease.
What is ONC201?
ONC201 is a novel, orally administered small-molecule drug that selectively targets the dopamine receptor D2 (DRD2) and mitochondrial caseinolytic protease P (ClpP). Originally developed by Oncoceutics, this innovative therapy has shown promising results in clinical trials for recurrent high-grade gliomas, including glioblastoma.
Mechanism of Action
ONC201 works through multiple pathways:
Induces tumor cell apoptosis by activating the integrated stress response (ISR).
Disrupts mitochondrial function in cancer cells, leading to energy depletion and cell death.
Modulates the tumor microenvironment, enhancing immune responses against glioma cells.
ONC201’s Approval and Launch in China
Following successful clinical trials demonstrating its efficacy and safety, ONC201 has been approved in China for the treatment of recurrent high-grade gliomas, including glioblastoma. The availability of ONC201 capsules marks a significant advancement in neuro-oncology, providing a much-needed therapeutic option for patients who have exhausted standard treatments like surgery, radiation, and chemotherapy.
Clinical Evidence Supporting ONC201
Phase II trials showed durable responses in some patients with recurrent glioblastoma, including tumor regression and prolonged survival.
Combination potential with other therapies, such as checkpoint inhibitors and radiation, is being explored to enhance efficacy.
Benefits of ONC201 for Glioma Patients
Oral Administration—Unlike intravenous chemotherapy, ONC201 capsules offer convenience and ease of use.
Favorable Safety Profile – Early trials indicate manageable side effects, primarily mild fatigue and gastrointestinal symptoms.
Targeted Action—Unlike traditional chemotherapy, ONC201 selectively affects cancer cells while sparing healthy tissue.
Dosing guidelines for ONC201 capsules
ONC201 (dordaviprone) is an investigational drug targeting the dopamine receptor D2 (DRD2) and the mitochondrial protease ClpP, currently being studied for recurrent high-grade gliomas (including glioblastoma) and H3 K27M-mutant diffuse midline glioma (DMG).
Standard Adult Dosing
625 mg orally once every week (taken on the same day each week).
Administered fasting (at least 2 hours before or after meals).
Pediatric Dosing (for H3 K27M-mutant DMG)
Weight-based dosing:
≥50 kg: 625 mg once weekly.
<50 kg: 375 mg once weekly.
Dose Adjustments for Toxicity
Grade 3+ adverse reactions: Temporary interruption until resolution to ≤Grade 1, then resume at a reduced dose (e.g., 375 mg weekly).
Recurrent toxicity: Further dose reduction or discontinuation may be required.
Key Considerations
Fasting Requirement: ONC201 absorption is improved on an empty stomach.
Clinical Trial Context: Most data come from Phase I/II trials (e.g., NCT03416530, NCT04732065).
Combination Therapy: Some trials explore ONC201 + ONC206 or radiation.
Adverse Effects
Fatigue, nausea, vomiting, dizziness, and rare cases, prolactin elevation.
Challenges and Future Directions
While ONC201 represents a major step forward, challenges remain:
Identifying biomarkers to predict which patients will respond best.
Expanding trials to include newly diagnosed gliomas and pediatric brain tumors.
Exploring combination therapies to overcome resistance mechanisms.
Conclusion
The launch of ONC201 capsules in China is a landmark achievement in the fight against brain gliomas. With its unique mechanism, oral delivery, and encouraging clinical data, ONC201 provides a symbol of optimism for patients and oncologists alike. As research continues, this therapy could become a cornerstone in glioma treatment, improving survival and quality of life for many.
Stay tuned for updates on ONC201 and other emerging brain cancer therapies!
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
About Susan Hau
Susan Hau is a distinguished researcher in the field of cancer cell therapy, with a particular focus on T cell-based approaches and cancer vaccines. Her work spans several innovative treatment modalities, including CAR T-cell therapy, TIL (Tumor-Infiltrating Lymphocyte) therapy, and NK (Natural Killer) cell therapy. Hau's expertise lies in cancer cell biolo…
✓ Reviewed for medical accuracy by the CancerFax review panel.
Medical Disclaimer
This article is for educational purposes only and should not replace medical advice, diagnosis, or treatment from a qualified oncology specialist. Every patient's case is different. Treatment decisions should always be made after a review of complete medical records by the treating medical team.
Treatment availability, eligibility, timelines, and access can change. Any clinical trial participation depends on detailed review and approval by the trial hospital or investigator.